Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Petition targets painkiller marketing in effort to curb overdose deaths.

Kuehn BM.

JAMA. 2012 Sep 26;308(12):1194-6. No abstract available.

PMID:
23011691
[PubMed - indexed for MEDLINE]
2.

A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose.

Rich BA, Webster LR.

Pain Med. 2011 Jun;12 Suppl 2:S59-65. doi: 10.1111/j.1526-4637.2011.01129.x. Review.

PMID:
21668758
[PubMed - indexed for MEDLINE]
3.

Direct-to-consumer prescription drug advertising: trends, impact, and implications.

Wilkes MS, Bell RA, Kravitz RL.

Health Aff (Millwood). 2000 Mar-Apr;19(2):110-28. Review.

PMID:
10718026
[PubMed - indexed for MEDLINE]
Free Article
4.

From the FDA: what's in a label? A guide for the anesthesia practitioner.

Chang NS, Simone AF, Schultheis LW.

Anesthesiology. 2005 Jul;103(1):179-85. Review. No abstract available.

PMID:
15983471
[PubMed - indexed for MEDLINE]
Free Article
5.

Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications.

Kopp SW, Bang HK.

Health Mark Q. 2000;17(3):39-56. Review.

PMID:
11010219
[PubMed - indexed for MEDLINE]
6.

The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.

Hayes TA.

Clin Pharmacol Ther. 1998 Jun;63(6):607-16. Review. No abstract available.

PMID:
9663174
[PubMed - indexed for MEDLINE]
7.

Chronic pain and addiction: challenging co-occurring disorders.

Pohl M, Smith L.

J Psychoactive Drugs. 2012 Apr-Jun;44(2):119-24. Review.

PMID:
22880539
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk